Metagenomi Therapeutics ROA 2022-2025 | MGX
Current and historical return on assets (ROA) values for Metagenomi Therapeutics (MGX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Metagenomi Therapeutics ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2025-09-30 | $-0.09B | $0.25B | -30.80% |
| 2025-06-30 | $-0.09B | $0.27B | -27.77% |
| 2025-03-31 | $-0.08B | $0.30B | -22.82% |
| 2024-12-31 | $-0.08B | $0.33B | -21.02% |
| 2024-09-30 | $-0.07B | $0.36B | -19.42% |
| 2024-06-30 | $-0.08B | $0.39B | -25.73% |
| 2024-03-31 | $-0.08B | $0.42B | -39.49% |
| 2023-12-31 | $-0.07B | $0.37B | -74.52% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.055B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.071B | 12.09 |
| BridgeBio Pharma (BBIO) | United States | $14.501B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.806B | 18.36 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.915B | 23.87 |
| Bausch Health Cos (BHC) | Canada | $2.222B | 1.58 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.310B | 9.44 |
| Taysha Gene Therapies (TSHA) | United States | $1.246B | 0.00 |
| Personalis (PSNL) | United States | $0.729B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.422B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.187B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |